(Q42162257)

English

Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy

scientific article published on May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 October 2017

Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy (English)

1 reference

Europe PubMed Central

17 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

adenocarcinoma of the lung

1 reference

based on heuristic

inferred from title

author name string

Yuh-Min Chen

1

1 reference

Europe PubMed Central

17 October 2017

Jacqueline Ming Liu

2

1 reference

Europe PubMed Central

17 October 2017

Teh-Ying Chou

3

1 reference

Europe PubMed Central

17 October 2017

Reury-Perng Perng

4

1 reference

Europe PubMed Central

17 October 2017

Chun-Ming Tsai

5

1 reference

Europe PubMed Central

17 October 2017

Jacqueline Whang-Peng

6

1 reference

Europe PubMed Central

17 October 2017

language of work or name

0 references

publication date

1 May 2007

1 reference

Europe PubMed Central

17 October 2017

1 reference

Europe PubMed Central

17 October 2017

109

1 reference

Europe PubMed Central

17 October 2017

1821-1828

1 reference

Europe PubMed Central

17 October 2017

9

1 reference

Europe PubMed Central

17 October 2017

Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Practical management of patients with non-small-cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

A targeted approach to reducing lung cancer mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22616

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22616

1 reference

Europe PubMed Central

17 October 2017

1 reference

Europe PubMed Central

17 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42162257&oldid=1935026858"